Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02160925

Enrollment

125

Registered

2014-06-11

Start date

2014-05-31

Completion date

2018-06-30

Last updated

2019-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical T1 Renal Mass

Brief summary

The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging for the diagnosis of renal oncocytomas.

Interventions

OTHERPreoperative 99mTc-Sestamibi SPECT/CT

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging * Scheduled to undergo surgery with either partial or radical nephrectomy * Age ≥18 years

Exclusion criteria

* Pregnancy * Evidence of nodal or distant metastases * History of other malignancy with concern for renal metastasis * Known allergy to technetium or sestamibi

Design outcomes

Primary

Measure	Time frame
Correlation of preoperative 99mTc-sestamibi SPECT/CT findings with tumor histology following surgical resection.	Within 2 weeks of surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026